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Objective: Radiotherapy (RT) elicits tumor cell death that leads to activation of 
dendritic cells (DC) and promotes a T-cell immune response. This type of cell 
death, termed immunogenic cell death (ICD), results in the release of immune 
signals (HMGB1 and ATP), and the cell surface translocation of calreticulin 
(CRT). TSA syngeneic murine model of mammary carcinoma were used in these 
experiments because of their ability to induce abscopal responses when treated 
with anti CTLA4 antibody, and therefore, a good “immunogenic” tumor model 
(Dewan et al. 2009). Experiments were done using wild-type cells, as well as 
TSA cells transfected with various plasmids that allow for easier recording. It has 
been shown that RT with X-rays is able to increase these three markers of ICD in 
a dose-dependent manner (Golden et al. 2014).  
    Less is known about the effects of higher linear energy transfer (LET) 
radiation and how it may impact tumor ICD. This study investigates the impact of 
increasing LET particle radiation on the expressed levels of these established 
ICD markers. High LET particle irradiation offers several potential therapeutic 
advantages over X-rays: increased cell kill, more focused dose distribution and 
	 vi	
more densely generated double stranded DNA breaks. This experiment 
investigates the immunogenic effects of high LET particle radiation compared to 
X-rays. We have previously demonstrated that ICD markers (ATP, HMGB1 and 
CRT) are increased with high LET ions when compared to X-ray treatment. In 
addition to in vitro experiments, a tumor vaccination model has been created to 
test the differences between X-ray RT and charged particle RT in vivo. Tumor 
cells were treated with either X-ray RT or charged particle RT. These irradiated 
tumor cells are then injected subcutaneously into a mouse and serves as a 
systemic vaccine, protecting a mouse from a subsequent challenge of non-
irradiated tumor cells. Cells treated with X-ray RT appear to have a vaccination 
effect that appears in a dose-dependent matter; with increasing radiation dose, 
we observed an increase in vaccination strength. The ability for irradiated TSA 
cells to serve as a vaccine appears to plateau at doses of 24 Gy. 
 
Results: Preliminary data suggest that the immunogenicity of tumor cells as 
measured by immune cell death signals appear to increase with ion irradiation at 
LET greater than 60 keV/µm when compared to X-ray irradiation at the same 
dose. These marker levels appear to decrease at LET greater than 110 keV/µm. 
Preliminary in vivo experiments show that mice injected with irradiated TSA cells 
are able to provide a systemic vaccination effect that appears to be correlated 
with the original dose of radiation. As the dose is increased from 2 Gy to 50 Gy 
X-rays, there is a correlative increase in vaccination effect. For mice that grew 
	 vii	
tumors with lower doses of radiation, the size of tumor growth was significantly 
slower than control groups.  
Conclusions: Using wild-type TSA cells, irradiated cells showed an increase of 
ICD markers when compared to non-irradiated cells. There was no significant 
difference between charged particle RT and X-ray RT in their ability to increase 
markers of ICD. Using the TSA cell line with plasmid transfections, increasing 
LET leads to increased release of ICD markers. The degree of release appears 
to plateau after 100 keV/um.  The TSA reporter cell line appears to show an 
increase in ICD marker expression when irradiated with high LET radiation. Our 
in vivo model shows that irradiated tumor cells injected subcutaneously into a 
mouse are able to induce an in situ vaccine effect so that subsequent challenge 
with non-irradiated tumor cells is able to reject tumor formation. Further studies 
are warranted to investigate the effects of LET and types of charged particle 
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 Ionizing radiation has been used in the clinic for the treatment of variety of 
diseases, most notably in the treatment of many cancers. Ionizing radiation is 
effective in the treatment of cancer because it has the ability to create irreparable 










Figure 1: Ionizing radiation leads to cell death. Radiation is an effective 
treatment option against cancer primarily due to its ability to cause irreparable 
DNA damage that leads to cell death. Figure reprinted from “Radiation-induced 
DNA damage and delayed induced genomic instability,” by Suzuki et al. 2003. 
Oncogene 22, 6988-6993. 
 
 
Many cancers form as solid tumors, while other cancers such as leukemia 
do not. Solid tumors have the ability to metastasize to distant organs, decreasing 
the prognosis for these patients. Treating cancer has gone through many 
milestones.  
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During the 20th century, three modalities emerged as the primary 
approaches to treating solid tumors – surgery, chemotherapy, and radiation 
therapy. Combining these treatments allowed for better prognosis.  In addition, 
scientists also discovered that radiation not only has the ability to treat cancer, 
but can also cause cancer by creating non-repairable DNA damage and 
mutations that accumulate during treatment. Now, radiation treatment has made 
many more advances since its advent. Some new radiation therapies include 
conformal proton beam therapy, stereotactic body radiation therapy, 
intraoperative radiation therapy, and heavy ion radiation therapy (Sudhakar 
2009).  
Radiation has typically been used for decades as a local treatment with an 
assumption that there were no effects outside of the radiation field.  The 
paradigm evolved that radiation therapy is quite effective for patients with 
localized disease, but patients with disease progressed to other organs still had 
poor prognosis. 
In 1953, a rare case was published of a patient who had metastatic 
disease and was cured. The doctor treating this patient, Dr. RH Mole, then 
challenged the notion that radiation is unable to act as a curative treatment for 
metastatic disease when he first coined the term “abscopal effect” in 1953 (Mole 
1953).  This phenomenon, which was largely dismissed for the next 50 years 
after it was first coined, refers to the ability of localized radiation to have systemic 
antitumor effects. As more case reports appeared, the abscopal effect 
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phenomenon, while still rare, gathered a lot of attention from researchers and 
physicians across the globe.  Many scientists are actively investigating how to 







Figure 2: History of the abscopal effect. Dr. RH Mole first coined the 
phenomenon in 1953. His hypothesis was largely dismissed for decades, but 
published case studies and the advent of immunotherapy have brought this 
phenomenon back in the spotlight (Figure reprinted from “Whole Body 
Irradiation—Radiobiology or Medicine?” by RH. Mole. 1953. The British Journal 
of Radiology. 26. 234-41.) 
 
 Radiotherapy (RT) elicits tumor cell death that leads to activation of 
dendritic cells (DC) and promotes a T-cell immune response.  In order for T cells 
to become activated and proliferate, they require multiple signals. The first signal 
is when the T cell receptor (TCR) first recognizes the MHC: peptide complex and 
the CD4/CD8 co-receptor recognizes the MHC complex. The second signal that 
is required for T cell proliferation is co-stimulation from CD28 and B7. T cells 
express CD28 that binds with a B7 (CD80/86) receptor from antigen presenting 
cells (APC). In the absence of CD28-B7 signaling, the antigen recognition is not 
enough to activate naïve T cells. When all requirements for activation are met, 
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signaling pathways are activated that leads to the production of cytokines such 












 Figure 3: T cells require two signals in order to proliferate. The first 
signal is between the TCR and the MHC:peptide complex. The second is 
between CD28 and B7. When all signals are achieved, T cell activation can occur 
(Figure reprinted from “APC-derived cytokines and T cell polarization in 
autoimmune inflammation” by I. Gutcher & B. Becher. 2007. The Journal of 
Clinical Investigation. 117(5), 1119-1127.) 
 
 
There are certain receptors that have the ability to block the co-stimulation, 
preventing T cell proliferation. Two main receptors that are known to block T cell 
proliferation, better known as checkpoint inhibitors, are CTLA-4 and PD-1. Many 
of these checkpoint inhibitors have important functions to humans and some 
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have evolved to promote successful reproduction, while some other functions are 
still unknown. When these receptors bind to their respective ligands (CTLA4 











 Figure 4: Checkpoint inhibitors inhibit immune activation. When 
CTLA4 binds B7 or when PD-1 binds PDL-1, T cells cannot be activated because 
co-stimulation is blocked. Scientists are using monoclonal antibodies as a form of 
immunotherapy to bind to checkpoint inhibitors, allowing for immune activation.  
(Figure reprinted from “Enterocolitis due to immune checkpoint inhibitors: a 
systematic review” by Soularue et al. 2018. Gut. 67(11), 2056.) 
  
 
Immune suppression is important at various points of the life cycle. When a 
mother becomes pregnant, and a fetus begins to grow, the mother’s cells that are 
in close contact with the fetus up-regulate the checkpoint inhibitor PD-1, as well 
as other immune modulators, to promote immune tolerance by inactivating the 
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maternal immune system at the placental-maternal interface. PDL-1 is expressed 
by syncytiotrophoblasts and cytotrophoblasts of the fetus (Guleria 2005). These 
cells are in close proximity with maternal blood and tissue that express PD-1.  If 
the fetus lost the ability to upregulate PDL-1, the mothers’ immune system would 
likely detect the fetus and determine it as a foreign antigen, resulting in fetal 
death.  
There are a number of mechanisms that tumor cells utilize to establish an 
immunosuppressive tumor microenvironment. Some of these capabilities include 
upregulation of immunosuppressive receptors that block T cell activation (PD-1 
and CTLA-4) and infiltration of myeloid-derived suppressor cells (Arina et al. 
2016). In addition, the presence of various molecules such as indoleamine 2,3 
deoxygenase (IDO) induces immunosuppression. IDO becomes overexpressed 
in response to interferon gamma in a variety of cancers and causes breakdown 
of trypophan in the tumor microenvironment. This reduces the ability of T cells 
and DC cells to combat the tumor (Soliman et al. 2010).  
 Scientists have paid special attention to the receptors that modulate our 
immune system. Many forms of immunotherapy are constructed using 
monoclonal antibodies or fusion proteins to bind to immunosuppressive 
receptors. When they bind to immunosuppressive receptors, these receptors fail 
to bind to their ligands, which allows for immune activation. For example, 
ipilimumab is a monoclonal antibody that targets the checkpoint inhibitor CTLA-4 
(Figure 5).  By doing so, CTLA-4 cannot bind to B7 and prevent T cell activation. 
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Therefore, ipilimumab allows for T cell proliferation and allows patients’ immune 
systems to more effectively fight off some cancers. Many pharmaceutical 
companies have significant interests in the new immunotherapies. 
Pembrolizumab is another monoclonal antibody that targets the other checkpoint 
inhibitor, PD-1. It prevents PD-1 from binding to its ligand, PDL-1, allowing for 
immune activation. Pembrolizumab hit the spotlight across the country after 
former US president Jimmy Carter was diagnosed with metastatic stage four 
melanoma.  This is an aggressive cancer and he was treated with radiation, 
chemotherapy, and immunotherapy. Defying the odds, his treatment has allowed 







Figure 5: Monoclonal antibodies are used to promote immune 
activation. Ipilimumab is a monoclonal antibody that binds to the checkpoint 
inhibitor CTLA-4. Doing so prevents the checkpoint inhibitor from binding to B7 
and allows co-stimulation for T cell activation. (Figure reprinted from “Ipilimumab: 
A novel immunostimulatory monoclonal antibody for the treatment of cancer” by 





Combining immunotherapy with radiotherapy can enhance our immune system, 








Figure 6: Radiation to primary tumor causes immune response. Radiation to 
the primary tumor causes release of neo-antigens which are taken up by antigen 
presenting cells (APC) and transported to the lymph nodes. At the lymph nodes, 
APC activates T cells, which travel to non-irradiated tumors creating an abscopal 
effect. (Figure reprinted from “Using immunotherapy to boost the abscopal effect” 




Established tumors are able to strive due to an immunosuppressive tumor 
environment (Golden et al. 2014).  A lot of cancer immunotherapy research is 
focused on manipulating the tumor microenvironment (TME) to promote an 
effective immune response. It has been shown that radiation is able to alter the 
TME by eliciting immunogenic cell death (ICD). ICD is characterized by the 
release of immune modulating signals, which include the release of high mobility 
group box 1 (HMGB1) and adenosine triphosphate (ATP), as well as the 























Figure 7: Three markers of ICD induced by RT. 
Panel A: Under normal conditions ATP is kept inside of cells. Upon ICD, ATP is 
release into the extracellular environment 
Panel B: Under normal conditions, HMGB1 resides in the cell nucleus. Upon ICD, 
HMGB1 is released into the extracellular environment 
Panel C: Under normal conditions, CRT is an ER resident chaperone protein. 
Upon ICD, CRT undergoes translocation to the cell surface.  
(Figure reprinted from “Radiation fosters dose-dependent and chemotherapy-




Previous studies have demonstrated a positive correlation between 
markers of immunogenic cell death (ICD) and irradiation dose with X-rays 
(Golden et al. 2014). Less is known about the effects of higher energy charged 
particle irradiation on ICD. Most forms of particle RT involve charged particles 
(electrons, protons, deuterium, helium, etc). This study investigates high-energy 
particle radiotherapy (proton, deuterium, and helium particles) and examines 
whether varying linear energy transfer (LET) charged particle irradiation elicits 
ICD in tumor cells.  
Radiation fosters tumor cell ICD and leads to the release of various 
markers into the TME that allows the host immune system to recognize and 
eliminate cancerous cells. Three hallmark components of ICD include the release 
of high mobility group box 1 (HMGB1), the release of adenosine-5’-triphosphate 
(ATP), and the cell surface translocation of calreticulin (CRT) (Sukkurwala et al. 
2014). HMGB1 is a DNA binding protein and toll-like receptor 4 mediated DC 
activator. ATP is a signaling factor that activates purinergic receptors on DCs 
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which causes secretion of interleukin-1 beta leading to subsequent priming of 
interferon gamma (IFN-γ) producing CD8+ T cells. CRT is an endoplasmic 
reticulum chaperone protein and strong DC “eat-me” signal (Golden et al 2014).  
These ICD markers work in concert to promote DC activation and stimulate cross 
priming and activation of CD8+ T lymphocytes. Recent evidence shows that X-
ray radiation and several chemotherapies lead to increased expression of these 
markers in vitro (Golden et al. 2014).  
Heavy particle RT has many advantages over lighter particles and X-ray 
RT. Because of the physical characteristics of particles, they have a 
characteristic peak where a majority of the energy gets deposited. The peak has 
been given the name “Bragg Peak,” and it is attractive to physicians because 
they are able to minimize side effects while depositing most of the radiation dose 
directly at the tumor.  Heavier particles such as helium and carbon ions have a 
larger mass than photons or X-rays and have limited scattering and maintain 






















Figure 8: Relative Biological Effectiveness increases as particle mass 
increases. Heavy particles have a greater RBE due to double stranded DNA 
breaks that are difficult for the host to repair. Protons have lower RBE than fast 
neutrons due to increased scattering. Intensity-modulated radiation therapy 
(IMRT) manipulates photon beams of radiation to conform to the tumor. Carbon 
ions (C) are one of the heaviest charged particles used in cancer radiotherapy. 
(Figure reprinted from “Heavy Ions in Cancer Therapy” by Pompos et al. 2016. 





The focus of these experiments is on protons, deuterium, and helium ion 
radiotherapy. Charged particle radiation has recently become more popular in 
clinics across the country mainly due to the potential of charged particle radiation 
delivery to spare normal tissue. Charged particle RT is able to delivery radiation 
more precisely to the tumor because of the characteristics of their Bragg peak 
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(Figure 9).  By taking advantage of this characteristic, charged particle RT can 
more effectively deposit the radiation dose at the tumor sparing healthy tissues 
and organs from radiation induced damage. For this reason, charged particle 
radiotherapy is used in treatment of many pediatric tumors and brain cancers 
while sparing healthy tissue vital for continued growth and development and 
minimizing unwanted side effects to critical structures. This study investigates the 
ability of charged particle radiation to elicit ICD and activate the immune system 




















Figure 9: Bragg peak dose depth curve for different types of RT. Whereas 
the dose depth curve for photons extends throughout the entire field, the curve 
for protons has a clear peak at 22 cm (defined as its Bragg peak). Carbon ions 
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have the most distinct peak and deliver a lower dose outside the radiation field 
(Figure reprinted from “Carbon Ion Radiation Therapy for Liver Tumors” by Wang 
et al. 2017. Practical Guides in Radiation Oncology Target Volume Delineation 












































Specific aims of this thesis include: 
 
1) Examine the ability of charged particle radiotherapy to elicit 
immunogenic cell death compared to X-ray radiotherapy  
 
 
2) Use various laboratory techniques such as flow cytometry to conduct 





We expect these studies show: 
 
1) Charged particle RT is able to increase immune modulating signals 
when compared to X-ray RT due to physical parameters (i.e. increased 
cell kill)  
 

























Reporter cell lines used in previous studies establishing the connection 
between X-ray RT and ICD were engineered to detect HMGB1, ATP, as well as 
cell surface CRT (Golden et al. 2014). Cells were derived from TSA (murine 
mammary carcinoma; syngeneic to BALB/c mice). Prior to irradiation, the cells 
were seeded in 1.5cm metal rings covered with a thin membrane made of Mylar. 
The cells were then irradiated at the Radiological Research Accelerator Facility 
(RARAF) through a Track Segment Charged-Particle Irradiator.  
 
In Vitro Assays 
 TSA mammary carcinoma cells were maintained DMEM (Gibco), which 
included 4.5g/L D-glucose and supplemented with 10% fetal bovine serum 
(HyClone Laboratories). In addition, TSA cells were maintained in 400ug/mL 
G418 (Gibco). TSA cells were grown in a humidified incubator (ThermoScientific) 
at 37 degrees Celsius and 5% CO2. 
 
HMGB1 
TSA cells were transfected with a fluorescent reporter, a pCMV6-AN-RFP 
plasmid encoding a HMGB1 with a red fluorescent protein C-terminal tag. 1 x 105 
TSA cells were seeded in 2 cm dishes. 2 mL of DMEM was added to the dish. 
After RT, cells were left to incubate for 72 hours. After 72 hours, the DMEM was 
collected and spun down in a centrifuge at 1400 RPM for 5 minutes. The 
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supernatant was collected and 275 uL of supernatant was added to six wells of a 
96 well plate. The plate was then inserted into a plate reader and fluorescence 
measurements were taken using Softmax Pro (Molecular Devices, San Jose, 
CA) and an excitation of 530 nm and emission of 593 nm. 
In addition to using transfected TSA cells, wild type TSA cells were also 
used to measure HMGB1 using an ELISA kit from IBL International (Hamburg, 
Germany) using the protocol provided. 
 
CRT 
 TSA cells were transfected with a DNA construct from the pEZ-M02 
vector that expresses CRT-HaloTag-KDEL fusion protein, a fluorescence-based 
reporter of cell surface localized CRT (Golden et al. 2014). 2 x 105 TSA cells 
were seeded in 2 cm dishes. 2 mL of DMEM was added to the dish. After RT, 
cells were left to incubate for 24 hours. A 1:1000 dilution of Halotag ligand Alexa 
Fluor 488 was made. After 24 hours, the old DMEM was aspirated and 750 uL of 
the Halotag solution was added to each dish. Cells were then left to incubate for 
30 minutes at 37 degrees Celsius and 5% CO2. After incubation, the Halotag 
solution was aspirated and 1 mL of PBS was added to each dish. Afterwards, cell 
scrapers were used to detach the cells from the plate wall. Cells were then 
transferred into 15 mL tubes and allowed to spin down for 3 minutes at 1350 
RPM. After centrifugation, the supernatant was aspirated and cells were re-
suspended in 1 mL of 4% paraformaldehyde in PBS. Tubes were covered in foil 
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and allowed to incubate for 20 minutes at 4 degrees Celsius.  After incubation, 
cells are centrifuged again, the supernatant is aspirated, and cells are 
resuspended in 500 uL of PBS. Cells are then filtered through a cell strainer and 
transferred into tubes for flow cytometry.  
 
ATP 
Wild type TSA cells were used to measure ATP using an ATP Kit from 
Promega using the protocol provided. 1 x 105 cells were seeded in 2 cm dishes. 
2 mL of media was added to the dish.  ATP release was measured in the 
medium 24 hours after RT using absorbance measurements taken on a 




γH2AX is a protein and a novel biomarker for DNA double stranded 
breaks. It is commonly used as an assay to assess DNA damage after RT.   2 x 
105 cells were seeded in a 2 cm dish. Cells were delivered RT and incubated for  
30 minutes. After incubation, cells were washed with 1 mL PBS.  Then, 500uL of 
2% paraformaldehyde in PBS was added and incubated at room temperature for 
20 minutes. The cells were then washed again in 1 mL PBS. Cells were then 
permeated with 100 uL methanol and incubated at -20 degrees Celsius for 20 
minutes.  Next, non-specific binding surfaces were blocked with 0.2% BSA/PBS 
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treatment. Cells were treated with 1:800 dilution of anti-γH2AX antibody (Cell 
Signaling, #2577) into the 0.2% BSA/PBS solution, covered with parafilm and 
incubated at room temperature for one hour. Parafilm was removed, antibody 
discarded and plates washed with 1 mL PBS. Second antibody was added at 
1:200 dilution of Alexia 488 conjugated anti-rabbit goat IgG (Molecular Probes, 
A11070) in 0.2% BSA/PBS solution.  Plates were covered and incubated at room 
temperature for one hour.  Plates were washed again; VectaSheild with DAPI 
was added for mounting and counter staining simultaneously. Samples were 
covered with a cover slip and staining observed as images with a fluorescence 
microscope.  
 
In vivo Assays 
In vivo experiments were conducted using wild type TSA syngeneic 
murine model of mammary carcinoma and Balb/c mice. All mice were treated 
under the guidelines and approved protocol of the Institutional Animal Care and 
Use Committee.  Female Balb/c mice that were 6-7 weeks old were obtained 
from Taconic Farms and stored at the Weill Cornell Medicine animal facility.  TSA 
cells were irradiated with various doses of X-ray RT. Cells were also treated with 
Mitoxantrone (MTX), a known chemotherapeutic ICD inducer.  After 24 hours, 1 x 
106 treated cells were injected subcutaneously into the left flank of Balb/c mice to 
serve as a systemic cancer vaccine. Negative control mice received injections of 
PBS. Mice were then challenged with 1 x 105 non-irradiated TSA cells two weeks 
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after the primary injection.  Mice are then followed over the next month and 
weekly measurements are taken recording percentage of tumor free mice and 
tumor size. One month after mice have been challenged, follow-up experiments 
were conducted to measure tumor specificity. An additional cell line, 4T1 
mammary carcinoma derived from Balb/c mice were used as a challenge in 
addition to a contralateral re-challenge with TSA on the opposite flank. 1 x 105 of 
both non-irradiated 4T1 and TSA cells were injected subcutaneously in order to 
show the original vaccinations specificity against TSA (Figure 14B). Mice 
continue to be followed throughout the experiment for additional three weeks or 
until ethical endpoints are achieved (tumor size becomes too large). The 
percentage of tumor-free mice was measured weekly. If the vaccination did not 
prevent tumor formation, then tumor size was measured weekly.   
 
 Additional in vivo experiments examined a lymphocyte panel collected 
from cells from lymph nodes of mice that were treated with different conditions. 
Balb/c mice were injected with 1 x 105 TSA cells irradiated with various doses of 
RT as well as PBS. Seven days after the primary injection, mice were sacrificed 
and the draining inguinal lymph node was dissected. Lymph nodes were then 
crushed, washed, and lymphocytes were collected. Processing of the lymph 
nodes and subsequent flow cytometry analysis was done on the MACSquant 
flow cytometer (Miltenyi Biotec) to test for the presence of various lymphocytes. 
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The markers used in this analysis include CD3, CD4, CD8, CD11c, CD11b, 
CD19, and CD25.  
The current protocol has been amended to add more cell lines for future 
experiments to see if other cell lines are able to produce a similar response. The 
next in vivo studies will test PANC02 cells, derived from pancreatic ductal 
adenocarcinoma from C57BL/6J mice. Pancreatic cancer is one that needs a lot 
of attention from cancer researchers and can benefit greatly from effective 
immunotherapies. More cell lines will be tested in the future to determine the 















Figure 10: In vivo vaccination model. Cells were irradiated with various 
types of RT and injected subcutaneously as a cancer vaccine. Mice were then re-




Delivering charged particle RT to cultured cells has several technical 
challenges that needed to be overcome. First, conventional cell culture dishes 
could not be used due to the restraints on delivering particle RT. In order to 
deliver particle RT, the distance between the cells and the particles needed to be 
minimized. For this reason, metal rings were used that contained a plastic film 
made of mylar that is six microns thick. Cells generally do not grow as well on the 
mylar as they do on plastic, treated dishes. Second, controlling the distance 
between the cells was still a challenge. Lighter particles such as protons have a 
larger range than heavier particles such as helium and carbon ions.  In this 
system, protons can travel a distance of 300 microns whereas helium can only 
travel 120 microns. This became important when an attempt was made to 
vaccinate mice using cells irradiated with helium. This experiment resulted in 
tumors appearing at the vaccination site, which suggested that the cells were not 
evenly irradiated. Cell survival confirmed this hypothesis as 5 Gy X-ray RT was 
inducing more cell death than cells irradiated with 20 Gy helium. In order to find a 
solution, multiple attempts were made to limit the distance that the particle needs 
to travel. The most promising solution has been putting the cells in a small 
suspension of medium. This appeared to give proper cell survival curves and will 
be a part of the protocol for future experiments.  
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 Another challenge posed during these experiments were the conflicting 
data that was obtained for the TSA wild-type versus TSA reporter cell lines. The 
reporter cell lines showed a dose dependent relationship between X-ray dose 
and markers of ICD release, while wild-type cells showed a peak at 5 Gy that 
decreased around 20 Gy. This made it hard to draw any conclusions and 
therefore an in vivo model was used. 
 
 Future experiments will involve our new method for particle RT. The 
experiments will be conducted in the same manner as our current in vivo model 
was done. Using this method, X-ray RT can be compared to particle RT to see 
which one is better at stimulating the immune system. These important studies 



















In Vitro Assays 
 
TSA Reporter Cell Lines 
 
Initial experiments tested 3 markers of ICD; ATP, HMGB1, and CRT levels 
were examined with genetically engineered cell lines. Results are all reported as 
fold-changes relative to the signal from non-irradiated cells. All experiments were 
replicated five times. Each treatment group had n = 5 dishes. 
For ATP measurements, when compared to non-irradiated controls, cells 
irradiated with 5 and 20Gy X-rays and with 5Gy 65, 80, 110, and 160 keV/µm 
helium ions resulted in fold-changes of 1.00 ± 0.05 (non-irradiated; Fold ± 
Standard Error), 2.33 ± 0.08, 3.27 ± 0.19, 3.24 ± 0.10, 3.99 ± 0.33, 4.12 ± 0.32, 
and 2.91 ± 0.16 respectively.  
For HMGB1 measurements, when compared to controls, cells irradiated 
with 5 and 20 Gy X-rays and with 5 Gy 65, 80, 110, and 160 keV/µm helium ions 
resulted in fold-changes of 1 ± 0.02 (non-irradiated), 1.43 ± 0.03, 1.72 ± 0.03, 
1.97 ± 0.06, 1.64 ± 0.03, and 1.61 ± 0.04, and 1.51 ± 0.03 respectively.  
For CRT measurements, when compared to controls, cells irradiated with 
5 and 20 Gy X-rays and with 5 Gy 65, 80, 110, and 160 keV/µm helium ions 
resulted in %CRT+ fold-changes of 1.00 ± 0.12 (non-irradiated), 2.32 ± 0.15, 3.07 
± 0.32, 3.16 ± 0.17, 3.01 ± 0.12, 2.74 ± 0.39, and 1.61 ± 0.15, respectively. 
	 25	
For all three markers, statistical analysis was performed using a paired 
Student’s t test. For the three markers examined, cells treated with RT showed a 
significant increase compared to non-treated cells (P < .05).   
Gamma-H2AX, a novel biomarker for DNA double-stranded breaks, 






































































































































Figure 11: TSA reporter cell lines were used to measure expression of 
HMGB1, CRT, and ATP in vitro after RT. Results show how these 3 markers of 
ICD vary with varying LET of 5 Gy helium irradiation and X-ray RT.  Data shown 
are the fold increase relative to non-irradiated cells ± S.E. Each experiment was 
replicated five times. 
 
TSA Wild-type Cells 
HMGB1 was also analyzed using an HMGB1 ELISA kit from IBL 
International and wild type TSA cells. TSA cells were irradiated with varying 
doses of X-ray RT and various LET of helium RT.  Statistical analysis was 
performed using a paired Student’s t test. Analysis shows no statistical difference 
between 5 Gy X-rays and 5 Gy helium at various LET (P > 0.05). All treatments 
showed a significant increase over non-treated TSA cells (P < .05)   
 
Figure 12: Wild-type TSA cells expression of HMGB1. Cells were irradiated 
with 5 Gy X-rays and helium of varying LET. Cell supernatants were collected 72 





































Data was collected from three separate experiments in triplicates (n=5 for each 
treatment group). All RT treated groups had a significant increase in HMGB1 




































Figure 13: Gamma-H2AX assay for cells exposed to RT.   A) The green color 
represents cell foci that have DNA that’s been damaged. Blue color shows cells 
under native conditions. B) Fluorescence measurements were quantified and 
graphed. Cells receiving 5 and 20 Gy X-rays, as well as 5 Gy of helium at varying 
LET were compared to cells receiving no RT. 
 
The two separate systems have brought us to two separate conclusions. 
In the genetically engineered TSA cells, there appears to be a dose-dependent 
response to X-ray RT, whereas the wild-type cells appear to have a maximum 
response at 5 Gy and less HMGB1 release at higher doses.  The conflicting data 
has led us to test our hypothesis with an in vivo model. 
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In Vivo Studies 
With increasing dose of RT, there was an increase in observed 
vaccination effect. TSA cells treated with 2 Gy produced a weak vaccination 
effect and frequently would grow a tumor at the challenge site suggesting that 2 
Gy is too low of a dose of radiation. Vaccination effect appears to be dose 
dependent with radiation dose. When TSA cells treated with 50 Gy RT were 



































PBS	 16	 0	 16	 100%	 16	 0	 0%	
MTX	 3	 0	 3	 100%	 1	 2	 66%	
2	Gy	 5	 3	 2	 40%	 3	 2	 40%	
10	Gy	 10	 5	 5	 50%	 5	 5	 50%	
24	Gy	 21	 0	 11	 100%	 4	 17	 81%	















































Figure 14: TSA Tumor Cell In Vivo Vaccination Results  
 
Panel A: Percentage of tumor free mice after vaccination with MTX or X-ray RT.  
Panel B: Four weeks after the initial challenge, naïve and prior vaccinated mice 
were challenged again with 4T1 and TSA. All naïve mice injected to TSA or 4T1 
grew tumors. Of the mice that were previously vaccinated, 80% of mice rejected 
growth of a TSA tumor, and 0% rejected growth of the 4T1 tumor showing 
immunological memory and antitumor specificity towards TSA. 
Panel C: Most vaccinated mice were able to reject tumor formation. Of the small 
percentage of mice that failed to reject a tumor, tumor growth and size was 
slower and smaller than unvaccinated mice with the exception of mice vaccinated 
with TSA cells with 2 Gy RT 
 
Once it has been established that irradiated tumor cells are able to serve 
as a vaccine for mice, another in vivo experiment was done to examine levels of 
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lymphocytes in the lymph nodes of each treatment group. The draining inguinal 
lymph node is collected seven days post vaccination with irradiated TSA cells 
and flow cytometry analysis was done to test for the presence of various 
lymphocytes. According to our experiments, mice vaccinated with cells that 
received X-ray RT had a statistically significant increase in CD19 B-cells (P < 










Figure 15: CD19 B-cell response to X-ray RT. Lymph nodes were harvested 
from mice one week post injection with irradiated TSA cells. Graph represents 
the percentage of cells expressing CD19, a cell marker for B-cells. Error bars 
represent the standard error of the mean.   
 
 
A comparison in the percentage of lymphocytes in each group was analyzed and 
compared to non-vaccinated mice. These results show that the injection of 
irradiated TSA cells stimulates a CD19 B cells response (Figure 16).  Further 



























vaccines ability to reject tumor formation. A CD19 depleting antibody will be 
administered into mice and the experiments will be repeated. If mice receiving 
this antibody fail to reject tumor formation, the vaccine we are suggesting is 




























































Figure 16: Presence of various lymphocytes in response to X-ray RT. The 
draining inguinal lymph node of each subject group was processed and run by 
flow cytometry analysis to test for the presence of various lymphocytes.   
Lymph nodes were removed from mice receiving injections of irradiated TSA 
cells. Flow cytometry analysis was performed to examine the presence of various 








































X-ray RT is an effective tool against cancer because it is able to create 
irreparable double stranded breaks that result in various forms of cell death 
including but not limited to autophagy, necrosis, and immunogenic cell death 
(Golden 2012). X-ray RT deposits radiation dose along each segment of the 
body that the beams travel through. In the clinic, a lot of recent focus in Radiation 
Oncology has been dose escalation, which allows clinicians to deliver higher 
doses of radiation to the tumor.  This has lead to the formation of new radiation 
treatments such as stereotactic body radiotherapy for many patients in the clinic. 
Another emerging field in Radiation Oncology that has gathered a lot of attention 
is charged particle RT.  Because of the physical properties of particles, they are 
able to effectively deposit more of the radiation dose to the tumor and less 
radiation dose to healthy tissue. As charged particles increase in mass, they 
experience decreased lateral scattering and results in higher efficiency dose 
deposition. Particle RT is not as common as X-ray RT, although it is becoming 
more frequently used in the clinic as more centers are opening up. There have 
been millions of patients treated worldwide with X-ray RT, however roughly 
15,000 people worldwide have been treated with carbon ion therapy, one of the 
heaviest charged particles delivered in the clinic (Table 1).  The small number of 
people treated with carbon ion therapy is mainly due to lack of access, as there 
are limited number of carbon ion centers worldwide. It is also significantly more 
expensive than traditional X-ray RT. 
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Table 1: Comparison of X-ray RT vs particle RT. Most patients worldwide are 
treated with X-ray RT. Only a small fraction of patients are treated with particle 
















There are also patient populations and cancers that benefit greater from particle 
RT compared to other cancers. For example, particle RT is especially important 
for pediatric tumors. Children are especially susceptible to ionizing radiation due 
to natural development. In addition, children are more prone to certain toxicities 
after ionizing radiation that can lead to neurocognitive deficits, neuroendocrine 
deficits, audiovisual toxicity, growth abnormalities, and second malignancies 
(Ludmir et al. 2018). For this reason, ensuring efficient dose deposition is critical 
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in order to reduce the side effects from radiation dose.  In addition to pediatric 
tumors, adult tumor subtype matters when deciding on what kind of RT is best. 
For example, the location of most breast tumors make them a poor candidate for 
particle RT. X-ray RT is well tolerated by breast tissue and tends to have good 
outcomes (both cosmetic and overall survival). In addition, sparing healthy tissue 
is not of main concern as it is easier to avoid delivering radiation to critical 
structures. X-ray RT is more economically reasonably for these patients as well. 
These are some of the reasons why particle RT is not commonly used for breast 
cancers. On the other hand, the location of other tumors makes them prime 
candidates for particle RT. For example, pancreatic tumors can take advantage 
of the physical properties of particle RT as there are other critical structures 
around the pancreas that make it more prone to toxicity and experiencing 
uncomfortable side effects for patients should they receive radiation dose.  
Pancreatic cancer is one of the leading causes of death in the United States. In a 
tri-institutional study in Japan, 72 patients with locally advanced pancreatic 
cancer were treated with carbon-ion RT.  Using particle RT for LAPC is promising 
because physicians are able to deliver larger doses to the tumor without giving 
patients severe toxicity because of more precise dose deposition. This study 
gathers data from three institutions and has reported high overall survival rates 
compared to patients with LAPC receiving X-ray RT, as well as no significant 


















    Figure 17: LAPC Patients OS after treatment with carbon ion RT. Results 
from three separate institutions show no significant difference amongst each 
other (P < 0.05). (Figure reprinted from “Multi-institutional Study of Carbon-ion 
Radiotherapy for Locally Advanced Pancreatic Cancer: Japan Carbon-ion 
Radiation Oncology Study Group (J-CROS)” by Kawashiro et al. 2018. 
International Journal of Radiation Oncology*Biology*Phsyics. 121(2), 288-293.) 
 
 
The study also compared their results with other published studies using X-ray 
RT and proton RT.  In a comparison between patients treated with intensity 
modulated RT, stereotactic body RT, and proton RT, those who were treated with 
carbon RT saw higher overall survival rates as well as lower GI toxicity (Table 2). 
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Table 2: A comparison of published studies on OS and GI toxicity for 
patients treated with different types of RT. Patients who were treated with 
carbon ion RT saw the greatest OS. Patients treated with proton ion RT also saw 
greater survival compared to those treated with intensity-modulated radiation 
therapy and stereotactic body radiation therapy. Table reprinted from “Multi-
institutional Study of Carbon-ion Radiotherapy for Locally Advanced Pancreatic 
Cancer: Japan Carbon-ion Radiation Oncology Study Group (J-CROS)” by 
Kawashiro et al. 2018. International Journal of Radiation 



































There are many advantages for using particle RT compared to X-rays. Aside 
from the advantages of the physical characteristics of particles, they may have 
an additional advantage in stimulating our immune system. It has been shown 
that X-rays are able to stimulate our immune system. Radiation is able to induce 
DNA damage that leads to the formation of micronuclei and leads to the release 
of DNA into the cytosol. DNA in the cytosol gets recognized by a cytosolic DNA 
sensor, which promotes signaling pathways that lead to the production of 
interferon genes. These interferon genes attract other immune mediators and 
initiate an immune response (Durante 2018).  While it has been shown radiation 
can induce micronuclei, it appears to be easier to induce with charged particles 
(Figure 18).   
In addition to DNA damage, RT also has the ability to combat the 
immunosuppressive TME by eliciting ICD in tumor cells. Radiation activates 
many pathways, a lot of which is still unknown. However, it has been shown that 
radiation induces release of HMGB1 and ATP, while causing relocation of CRT 
from the ER to the cell surface. These three markers work in concert to produce 
a cytokine milieu that ultimately leads to DC cross priming of CD8 cytotoxic T 


















Figure 18: Carbon ions vs X-rays ability to induce micronuclei in 
binucleated cells.  This figure shows that Carbon ions are able to induce greater 
number of micronuclei at much smaller doses when compared to X-ray RT 
(Figure reprinted from “Radiation-Induced Chromosomal Aberrations and 
Immunotherapy: Micronuceli, Cytosolic DNA, and Interferon-Production Pathway” 
by Durante et al. 2018. Frontiers in Oncology. 8, 192) 
 
 
A lot of research in Radiation Oncology has recently evolved with a major 
focus on immunotherapy. A lot of attention has been placed on immunotherapy 
as physicians shared success stories with rare numbers of cancer patients whom 
have been cured of diseases thought to be incurable. This has led to the highly 
advanced immunotherapy treatments that are saving many lives in the clinic. The 
abscopal effect, while rare, is a common goal for many physicians and in the 
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clinic. Many scientists are also using immunotherapy in conjunction with 






















Table 3: RT used in conjunction with immunotherapy to try and boost the 
abscopal effect. Different RT regimens and immunotherapies were used in 
various preclinical models (Table reprinted from “Using immunotherapy to boost 










































Various treatment options allow physicians to try different combinations to try and 
optimize an immune response that would lead to an abscopal effect. However, 
nearly all of these clinical trials use X-rays as the form of radiation, rather than 




















 Given the success of particle radiotherapy for certain patient populations, 
there likely will be more particle RT clinics opening up worldwide. Particle RT has 
a number of advantages over X-ray RT of which the science community is 
becoming more and more aware. While other countries outside of the United 
States begin opening up heavy ion centers like the carbon ion center in Japan, 
the US remains slow behind the pack. Certain clinics are catching slowly in the 
US, with Memorial Sloan Kettering Cancer Center being one example by recently 
adopting proton RT capabilities. However, given the impressive results that 
cancer patients are seeing after carbon ion therapy, expect to see charged 
particle capabilities becoming more commonplace in the United States and 
across the globe. Combining particle RT with immunotherapy offers promising 
results. The TME is full of immunosuppressive signals (Figure 19). If clinicians 
are able to alter the TME to allow immune activating pathways to be activated, it 
can potentially answer the question on how to make the abscopal effect more 
common. Finding the optimum combination of particle RT with chemotherapy and 
immunotherapy may be able to offer cures to many more patients as well as 







































Figure 19: Established tumors are embedded in an immunosuppressive 
tumor microenvironment. With strong immunosuppressive signals, cancers are 
able to shut down our immune system and prevent tumor rejection by the host 
(Figure reprinted from “Combining radiotherapy and cancer immunotherapy: a 
paradigm shift” by S.C. Formenti & S. Demaria. 2018. Journal of the National 
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